论文部分内容阅读
目的评价吉非替尼对非小细胞肺癌患者生活质量的影响。方法对68例应用吉非替尼的非小细胞肺癌患者治疗前后生活质量进行统计学分析,生活质量分析采用欧洲癌症研究和治疗组织(European Organization for Research and Treatment of Cancer,EORTC)简体中文版EORTCQLQ-C30和QLQ-LC13问卷对治疗前、后症状和生活质量的改变进行评价。结果68例患者完成了问卷调查。治疗后患者5种功能状态(躯体、角色、情感、认知、社会)及整体生活质量评分均值显著增加,与治疗前相比差异有显著性(P<0.05)。治疗后乏力症状评分的均值显著降低,与治疗前相比差异有显著性(P<0.05),治疗后肺癌相关症状(咳嗽、胸痛、呼吸困难)评分的均值显著降低,与治疗前相比差异有显著性(P<0.05)。症状和生活质量的改善与疾病控制相一致。生活质量改善者生存延长。结论吉非替尼可改善晚期非小细胞肺癌患者的症状和生活质量。
Objective To evaluate the effect of gefitinib on quality of life in patients with non-small cell lung cancer. Methods The quality of life of 68 NSCLC patients treated with gefitinib was statistically analyzed before and after treatment. The quality of life was analyzed by the European Organization for Research and Treatment of Cancer (EORTC) Simplified Chinese version EORTCQLQ -C30 and QLQ-LC13 questionnaires before and after treatment, symptoms and quality of life changes were evaluated. Results 68 patients completed the questionnaire. After treatment, the five functional status (body, character, emotion, cognition, social) and the overall quality of life score significantly increased, with significant difference compared with that before treatment (P <0.05). After treatment, the average score of fatigue symptom score was significantly lower than that before treatment (P <0.05). After treatment, the mean value of lung cancer-related symptoms (cough, chest pain, dyspnea) was significantly lower than that before treatment There was significant (P <0.05). The improvement in symptoms and quality of life is consistent with disease control. Quality of life improved life extension. Conclusion Gefitinib can improve the symptoms and quality of life in patients with advanced non-small cell lung cancer.